Clinical trials: Movement Abnormalities
Multiple System Atrophy (MSA), Healthy Adult
Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies
This is a single-center, open-label clinical study designed to evaluate the imaging characteristics and safety of [¹⁸F]MODAG-009 in participants with Parkinson's disease (PD), Multiple system atrophy (MSA), and Healthy controls…
- Conditions
- Multiple System Atrophy (MSA), Healthy Adult, Parkinson Disease
- Trial name
- MODAG-009-P1-0 (NCT07640555)
- Testing
- [¹⁸F]MODAG-009 PET imaging
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- MODAG GmbH
Chronic Motor or Vocal Tic Disorder, Tourette's Disorder
Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder
The purpose of this trial is to demonstrate the efficacy and safety of aripiprazole in children and adolescents aged 6~18 years with chronic tic disorders or Tourette's disorder
- Trial name
- NCT00706589
- Testing
- aripiprazole
- Where
- 6 sites in South Korea
- Volunteers
- 61 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Parkinson Disease
Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg
The purpose of this study was to determine whether the administration of BIA 6-512 (25 mg, 50 mg, 75 mg and 100 mg) at steady-state affects the pharmacokinetics of levodopa when administered in combination with a single-dose of…
- Trial name
- NCT03097211
- Testing
- BIA 6-512, Madopar® 250, Nebicapone
- Where
- Portugal
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
Levodopa Concentration Profile With Stalevo 75/125 mg
The purpose of this study is to confirm that the dose levels and dosing frequency utilising the new Stalevo strengths would result into more stable levodopa plasma levels.
- Trial name
- NEWSTA (NCT01070628)
- Testing
- Stalevo (levodopa/ carbidopa/ entacapone), Sinemet (levodopa/carbidopa)
- Where
- Finland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Parkinson Disease
A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease
This is a phase 2 study designed to assess the safety, tolerability and efficacy of NLY01 in subjects with early untreated Parkinson's disease (PD).
- Trial name
- NCT04154072
- Testing
- NLY01, Vehicle
- Where
- 61 sites in United States, Canada
- Volunteers
- 255 people
- Sponsor
- Neuraly, Inc.
Parkinson's Disease
A Trial of MitoQ for the Treatment of People With Parkinson's Disease
In Parkinson's Disease, the mitochondrial membranes in cells that produce dopamine become damaged by oxidants, leading to the death of these cells and progressive tremor, slowness of movement and the loss of neurons in the…
- Trial name
- NCT00329056
- Testing
- MitoQ
- Where
- 13 sites in Australia, New Zealand
- Volunteers
- 128 people
- Sponsor
- Antipodean Pharmaceuticals, Inc.
Idiopathic Parkinson's Disease
Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
This is a Phase 3, 52-week, open-label, flexible-dose, multinational, multicenter study to evaluate the safety and tolerability of istradefylline 20 or 40 mg/d in subjects with moderate to severe PD with motor fluctuations and…
- Trial name
- NCT02610231
- Testing
- Istradefylline 20 mg or 40 mg
- Where
- 55 sites in United States, Canada and 6 more
- Volunteers
- 239 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Parkinson Disease
A Study of AB-1005 Gene Therapy in Japanese Adults With Moderate Parkinson's Disease (J-REGENERATE-PD)
The objective of this Phase 2, open-label, single group, one-time, fixed-dose study is to assess the safety and efficacy of bilateral intraputaminal infusion of AB-1005 (AAV2-GDNF gene therapy) in Japanese patients with moderate…
- Trial name
- NCT07566429
- Testing
- AB-1005
- Where
- 6 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Bayer
Parkinson's Disease
Pharmacokinetic Study in Healthy Males
The purpose of this study is to investigate the pharmacokinetics of levodopa, carbidopa, 3-OMD and ODM-104 after repeated doses of 3 levodopa formulations given in combination with carbidopa and ODM-104.
- Trial name
- NOCOF (NCT02312232)
- Testing
- levodopa, carbidopa, ODM-104
- Where
- Finland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Parkinson's Disease
PK, PD and Safety of Multiple Doses of V1512 Tablets in PD Patients Compared to Standard Levodopa/Carbidopa Oral Tablets
The purpose of the study is to determine if the pharmacokinetic profile of V1512 is similar or better than existing medications for the treatment of Parkinson's Disease
- Trial name
- NCT00491998
- Testing
- V1512, V1512 and Entacapone
- Where
- Italy
- Volunteers
- 27 people
- Sponsor
- Vernalis (R&D) Ltd
Parkinson Disease
The Use of Telerehabilitation to Improve Movement Outcomes for Patients With Parkinson Disease
The goal of this pilot randomized clinical trial was to assess the feasibility of telerehabilitation (TR) for patients with Parkinson\'s Disease (PD). The main questions it aims to answer are: 1.
- Trial name
- NCT06246747
- Testing
- In clinic physical therapy, Telerehabilitation only
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Wizecare
Healthy, Epilepsy
Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
The human brain presents outstanding challenges to science and medicine. Brain function and structure span broad spatial scales (from single neurons to brain-wide networks) as well as temporal scales (from milliseconds to years).
- Conditions
- Healthy, Epilepsy, Psychosis, Essential Tremor
- Trial name
- NCT05769933
- Testing
- Simultaneous EEG-fMRI at 7 Tesla, Structural MRI at 7 Tesla
- Where
- Switzerland
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- CSEM Centre Suisse d'Electronique et de Microtechnique SA - Recherche et Developpement
Lewy Body Disease
A Phase I Study of GT300 in Healthy Subjects
Descriptive safety and pharmacokinetics of GT300, exploratory biomarker effects for the evaluation of the effect of GT300 on the autophagy-lysosomal pathway (ALP), food effect on PK and fasting effect on biomarkers.
- Trial name
- NCT04963855
- Testing
- GT300, Microcrystalline cellulose
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Generian Pharmaceuticals, Inc.
Parkinson Disease
LFP Beta aDBS Feasibility Study
The purpose of this study is to use local field potentials as control signals for adjusting DBS stimulation settings under varying patient states and to assess patient outcomes.
- Trial name
- NCT03446833
- Testing
- The LFP Beta aDBS System
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- MedtronicNeuro
Parkinson Disease
Study to Assess Pharmacokinetics of Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Parkinson's Disease Patients
The purpose of this study is to assess the PK of AP-CD/LD given at dose of 50/500mg three times daily compared to CD/LD immediate release (Sinemet) 1.5 tablets of dose of 25/100 given 5 times per day in Parkinson's Disease…
- Trial name
- NCT03576638
- Testing
- Accordion Pill Carbidopa/Levodopa, Sinemet CR 25Mg-100Mg Extended-Release Tablet
- Volunteers
- 12 people
- Sponsor
- Intec Pharma Ltd.
Parkinson's Disease
Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China
Rasagiline has been developed for the treatment of Parkinson's Disease (PD), as monotherapy in early PD patients not treated with levodopa, and as adjunct therapy to levodopa in levodopa-treated PD patients with motor…
- Trial name
- NCT01556165
- Testing
- rasagiline
- Where
- 15 sites in China
- Volunteers
- 130 people
- Sponsor
- H. Lundbeck A/S
Multiple System Atrophy
Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)
To test the clinical effect of rasagiline on subjects with MSA of the parkinsonian subtype.
- Trial name
- NCT00977665
- Testing
- rasagiline mesylate
- Where
- 47 sites in United States, Austria and 10 more
- Volunteers
- 174 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Parkinson Disease
Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease
The purpose of the study is to demonstrate the safety and effectiveness of adaptive DBS (aDBS) for Parkinson's disease.
- Trial name
- ADAPT-PD (NCT04547712)
- Testing
- Adaptive DBS
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 85 people
- Sponsor
- MedtronicNeuro
Parkinson Disease
A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa
This is a Phase III, multicentre, randomised, double-blind, placebo-controlled study to evaluate the effects of 100 mg safinamide, administered orally once daily (OD), in Chinese Parkinson's disease (PD) patients, experiencing…
- Trial name
- NCT03881371
- Testing
- Safinamide
- Where
- 31 sites in China
- Volunteers
- 307 people
- Sponsor
- Zambon SpA
Idiopathic Parkinson's Disease
Evaluating Safety, Tolerability, and Efficacy of Autologous MitoCell Transplantation in Subjects With Idiopathic Parkinson's Disease
Primary Objective: To assess the safety profile of autologous MitoCell administered to subjects with idiopathic Parkinson's disease (PD) Secondary Objective: To explore the efficacy and safety of MitoCell given as the recommended…
- Trial name
- NCT05094011
- Testing
- Aadipose-Derived Mesenchymal Stem Cells
- Volunteers
- 9 people
- Sponsor
- Taiwan Mitochondrion Applied Technology Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.